Collectively, EF-treatment could suppress neuroinflammation by alleviating microglial activation via inhibiting MAO-B activity after brain ischemia, providing a novel and promising therapeutic agent for ischemic stroke (Figure 6). Here, MAOB is linked to ischemic stroke.